Knight Therapeutics Inc T.GUD

Revenue comparison 10 years later

[GoldenInvestor]

2011, Paladin Labs :  $141 Million  , approximate
2021, Knight Therapeutics - $243 Million, approximate

[wofats]

There is about 5 times as many shares of Knight so we are close to being halfway there I would think. If revenue is 80+ for this quarter there is a good chance 300 is within grasp for this year. Ebitda will start to be large enough so there maybe interest from others so some share price increase is visual . As new drugs and territories are added into the mix now , price drops like this will

[EbbFlow88]

My thoughts exactly. They are certainly buying back here but the volume hasn't been very high so it seems buybacks are muted to save for a deal around the corner. Or they see a bigger market panic event to really put the buybacks to work. 

[MrMugsy]

Note that the shelf prospectus should expire in early 2023 (Jan 23 2023 ?) I believe this was positioned to take advantage of ATE's 346 chronic drug in South America - which didn't happen for obvious reasons. I'm going to assume the shelf prospectus gets extended and waits for ATE's 346 acute drug. Starting Phase 2 - 3rd Molar Extraction ... likely on September 28th - next week

[longrun86]

The shelf prospectus provides for optionality and I see it being wise to keep it going. Management and the Board are likely averse to raising equity at these prices but the debt possibility of the shelf prospectus is interesting given that the financial assets of Knight will start rolling over and could be used to repay in addition to cash flow from operations. Based on the last call, it is

[MrMugsy]

Absolutely adverse at these prices ... they have always been gungho to go to market "only" at higher valuations.  Therefore the next one would need to be over $10. But - value and opportunity would trump the desire to go to market at hire valuations ... unless they can pay for the deals in other ways (as you mentioned). Nothing is as true as these two words ... Long Game ! Nothing